ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.84
−0.41%Oct 5, 2026, 20:05 UTC
Aligos Therapeutics announced that five abstracts were accepted for presentation at the American Association for the Study of Liver Disease's The Liver Meeting 2026, to be held November 5-9, 2026 in Denver, Colorado.
Source:Sep 15, 2026, 20:07 UTC
Aligos Therapeutics amended its lease with Britannia Biotech Gateway Limited Partnership, extending the term to March 31, 2034 with escalating rent, a 10-month abatement, and an early termination option.
Aug 6, 2026, 00:00 UTC
Aligos Therapeutics reported Q2 2026 financial results with revenue of $27.8 million and a net loss of $1.5 million.
Jul 13, 2026, 12:00 UTC
Aligos Therapeutics completed enrollment in the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV infection.
Source:Jul 6, 2026, 20:05 UTC
Aligos Therapeutics received a $25M upfront payment from an exclusive license deal with Xiamen Amoytop Biotech for pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection.
Source:Jun 26, 2026, 00:00 UTC
Aligos Therapeutics, Inc. elected Bridget Martell and Carole Nuechterlein as Class III directors effective June 25, 2026.